Friday, May 11, 2012

OncoMed Pharmaceuticals Files For IPO

Redwood City-based OncoMed Pharmaceuticals filed for an IPO Friday, saying that it is looking to raised up to $115M on the NASDAQ Global Market as OMED. The firm's IPO is being underwritten by Jefferies, Leerink Swann, Piper Jaffray, and BMO Capital Markets. OncoMed is a developer of monoclonal antibody therapeutics targeting cancer stem cells. The firm is backed by U.S. Venture Partners, Latterrel Venture Partners, GlaxoSmithKline, The Vertical Group, Morgenthaler Partners, Phase4 Ventures, Delphi Ventures, Adams Street Partners, along with others.